Talazoparib in the treatment of breast cancer. Analysis of the real-world evidence
Summary. Breast cancer (BC) dominates the oncological morbidity and mortality of women in Ukraine, always ahead of other oncology. With early detection, BC usually has a favorable prognosis. In contrast, metastatic disease, although amenable to treatment, remains virtually incurable with an overall survival (OS) of approximately 3 years and a 5-year survival rate of only 25% [1]. The improved availability of increasingly effective systemic therapeutic methods combined with early detection has a positive effect on survival rates, although the treatment of patients with metastatic (m) HSCs is still primarily focused on prolonging survival and maintaining quality of life [2]. But, despite the increase in the number of women living with mBC and their treatment options, little is known about the results in routine clinical practice [3]. This is especially true for treatments outside of second- or third-line strategies and the burden of side effects, for which strategies may vary across clinical trials. In such conditions, the analysis of data from real clinical practice is vital to improve the treatment of the disease.
Leave a comment